MVI 816

Drug Profile

MVI 816

Alternative Names: PAP Vaccine - Madison Vaccines; pTVG-HP

Latest Information Update: 21 Aug 2015

Price : $50

At a glance

  • Originator Madison Vaccines
  • Developer Madison Vaccines; University of Wisconsin-Madison
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 19 Aug 2015 Phase-II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Treatment-resistant) in USA (Parenteral)
  • 23 Jun 2014 Madison Vaccines initiates expansion in a phase II trial in Prostate cancer (first-line therapy, hormone-naive patients) in USA
  • 23 Jan 2014 MVI 816 is available for licensing as of 23 Jan 2014. http://www.madisonvaccinesinc.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top